TICKERNERD
Menu
DMRAHealthcare · Biotechnology

DMRA Stock Forecast: Damora Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$31
+1.77% on the day

The 10 Wall Street analysts covering Damora Therapeutics, Inc. hold a median 12-month price target of $45 — +45.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 46 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$1.9B
Ticker Nerd rank
46 / 100
Median analyst target
$45
Analysts covering
10
Total return, dividends reinvested
1W
−0.6%
1M
−6.5%
YTD
+34.1%
1Y
+812.6%
From 52W high
−9.7%
From 52W low
+1095.5%
$3
$34
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DMRA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Damora Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
46 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
97
Accruals
84
Value
67
Volatility
53
Quality
43
Size
37
Revisions
36
Issuance
27
Growth
18

Momentum (97): The shares have been drifting up relative to others.

Growth (18): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

DMRA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DMRA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50Oct 25Jan 26Apr 26Jul 26DMRAHigh $51Median $45Low $40

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says10 analysts
10 Buy0 Hold0 Sell
Low $40Median $45High $51

The green dot is the last close — the median target sits +45.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
30 July 2026WedbushMaintainsOutperform$35 → $40
27 July 2026JefferiesInitiatesBuy$50
21 July 2026HC Wainwright & Co.ReiteratesBuy$45
21 July 2026HC Wainwright & Co.ReiteratesBuy—
12 June 2026WedbushReiteratesOutperform$35
12 June 2026WedbushReiteratesOutperform—
11 June 2026HC Wainwright & Co.InitiatesBuy$45
11 June 2026HC Wainwright & Co.InitiatesBuy—
28 May 2026WedbushInitiatesOutperform—
24 Apr 2026RBC CapitalInitiatesOutperform—
25 Mar 2026Evercore ISI GroupInitiatesOutperform—
17 Feb 2026GuggenheimMaintainsBuy—
17 Feb 2026UBSInitiatesBuy—
7 Jan 2026Leerink PartnersInitiatesOutperform—
8 Dec 2025GuggenheimMaintainsBuy—
1 Dec 2025GuggenheimInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DMRA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

DMRA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Damora Therapeutics, Inc. (DMRA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−7.8×

Cheaper than 92% of US stocks

Price / sales
—
Price / book
4.9×

Cheaper than 22% of US stocks

EV / EBITDA
−15.5×

Cheaper than 87% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−99.7%

Higher than 13% of US stocks

Return on assets
−21.6%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

DMRA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
DMRADamora Therapeutics, Inc.$1.9B
46
RXRXRecursion Pharmaceuticals, Inc.$1.8B
41
NTLAIntellia Therapeutics, Inc.$1.8B
50
SEPNSepterna, Inc.$1.8B
89
AGIOAgios Pharmaceuticals, Inc.$1.9B
81
GHRSGH Research PLC$1.9B
65
TSHATaysha Gene Therapies, Inc.$1.9B
46

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Damora Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DMRA news & analysis

Damora Therapeutics: Competition Validates The Target While Its Portfolio Creates The Upside

Seeking Alpha · 12 Aug 2026positive

Damora Therapeutics is advancing a differentiated portfolio targeting mutant calreticulin (mutCALR) in essential thrombocythemia and myelofibrosis. Its lead candidate, DMR-001, offers superior potency and half-life over comparators, with proof-of-concept data expected mid-2027 and a potential Phase 3 start in mid-2028.

Why it matters — A Damora Therapeutics watcher would care because the article highlights competitive validation of its target and positions the company's pipeline and lead candidate's advantages as the basis for future upside potential.

Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis

GlobeNewsWire · 5 Aug 2026positive

Damora Therapeutics announced the initiation of the global Phase 1/1b CLARITY-101 clinical trial of DMR-001, an investigational antibody therapy targeting mutant calreticulin, in patients with mutCALR-driven essential thrombocythemia and myelofibrosis, following health authority approval. The company noted that DMR-001 is designed for once-monthly subcutaneous dosing and that preclinical studies showed it had greater potency and a longer half-life than a reference anti-mutCALR antibody.

Why it matters — This marks the start of clinical testing for DMR-001, a lead pipeline candidate for Damora, and provides the first clinical data readouts that could validate its preclinical profile in a defined patient population.

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 3 Aug 2026neutral

Damora Therapeutics announced that on August 1, 2026, it granted equity awards to six newly-hired, non-executive employees. The inducement grants were approved by the independent Compensation Committee and made as material inducements to employment acceptance under Nasdaq Listing Rule 5635(c)(4).

Why it matters — A DMRA watcher would care because this shows the company is hiring and incentivizing new employees through equity, a routine governance disclosure with no direct impact on its commercial or clinical outlook.

FAQ

Frequently asked questions about DMRA stock

What is the DMRA stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Damora Therapeutics, Inc. have a median 12-month price target of $45, with estimates ranging from $40 to $51. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DMRA stock a buy right now?

Of the 10 analysts covering Damora Therapeutics, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Damora Therapeutics, Inc. 46 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DMRA?

As at 22 Aug 2026, Damora Therapeutics, Inc. ranks 46 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (97 of 100).

Will DMRA stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +45.9% from the last close, and Ticker Nerd's factor model ranks Damora Therapeutics, Inc. 46 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DMRA stock forecast for 2030?

No analyst covering Damora Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DMRA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $51 over the next 12 months.

How has DMRA stock performed over the past year?

Damora Therapeutics, Inc. returned +812.6% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Damora Therapeutics, Inc. do?

Damora Therapeutics, Inc. is a clinical-stage biotechnology company developing small molecule therapeutics targeting fibrosis, cancer, inflammation, and related diseases.

What is the latest news on DMRA?

The most recent item we track (Seeking Alpha, 12 Aug 2026): "Damora Therapeutics: Competition Validates The Target While Its Portfolio Creates The Upside". Damora Therapeutics is advancing a differentiated portfolio targeting mutant calreticulin (mutCALR) in essential thrombocythemia and myelofibrosis. Its lead candidate, DMR-001, offers superior potency and half-life over comparators, with proof-of-concept data expected mid-2027 and a potential Phase 3 start in mid-2028.

Company

About Damora Therapeutics, Inc.

Damora Therapeutics, Inc. is a clinical-stage biotechnology company developing small molecule therapeutics targeting fibrosis, cancer, inflammation, and related diseases. Its lead candidates include GB3226, a preclinical dual inhibitor of ENL-YEATS and FLT3 aimed at blood cancer indications such as acute myeloid leukemia and myeloproliferative neoplasms, and GB1211, an oral galectin-3 inhibitor for various oncology and liver disease applications. The company focuses on advancing innovative treatments that address unmet needs in hematologic malignancies and fibrotic conditions through precise molecular targeting. Damora Therapeutics, Inc. operates in the biopharmaceutical sector, contributing to the pipeline of novel therapies for severe diseases by leveraging expertise in inhibitor design and preclinical development. Founded in 2011 and headquartered in Copenhagen, Denmark, it plays a role in the global effort to improve patient outcomes in oncology and fibrosis through targeted small molecule approaches.

CEO Ms. Jennifer A. Jarrett M.B.A. · 7 employees · United States · https://www.damoratx.com